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Xno 30-day survival in the venoarterial cohort (n ¼ 15). They
also noted that the venoarterial group had 30 severe compli-
cations, compared with 9 complications in the venovenous
group. For children who require ECMO support for respira-
tory reasons, the venoarterial mode is often used with con-
cerns about hemodynamic instability developing from
respiratory failure. We used venovenous ECMO on 1 occa-
sion recently for posttransplant pneumonia, and the patient is
alive at 10 months. We are now more likely to use the veno-
venous configuration in the appropriate clinical setting.
Interestingly, we noted that the mean time for institution
of ECMO for PGD after lung transplant was shorter for
the 4 survivors than for the 14 nonsurvivors (8.5 hours vs
75 hours). Although the number of patients was small, this
may indicate that patients who are supported with ECMO
earlier may do better than patients who are treated with lon-
ger periods of more aggressive ventilatory strategies before
resorting to ECMO.We are nowmore likely to consider ear-
lier institution of ECMO rather than persisting with aggres-
sive ventilatory strategies in managing severe PGD.
CONCLUSIONS
The need for perioperative ECMO support is associated
with significant morbidity and mortality in the pediatric
lung transplant population. A subset of patients who can
be weaned from ECMO in the preoperative setting have
greater likelihood of survival. Extracorporeal support should
be cautiously offered to children with intractable respiratory
failure who are awaiting a primary (not reoperative) lung
transplant and to children with severe PGD or pneumonia af-
ter lung transplant for whommore conservative therapy does
not work. Earlier institution of ECMO for severe PGD may
possibly be protective.
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Dr Victor Morell (Pittsburgh, Pa). Dr Puri and associates pre-
sented their extensive experience with preoperative and postopera-
tive ECMO support in their pediatric lung transplant population. I
would have to admit that at Children’s Hospital of Pittsburgh, we
consider preoperative ECMO a contraindication for lung trans-
plant; however, there is certainly adult literature that would support
transplants for patients with ECMO support, and the results have
been reasonable.
I have 3 questions, Dr Puri. With the limited availability of or-
gans, what is the current management at your institution for patients
with ECMO support? Are they still listed?
Dr Puri. The short answer is no, and our results reflect that. We
had lower than 15% survival for patients supported by ECMO go-
ing into lung transplantation, and organs, as you say, are scarce.
Therefore we delist the patients when they are supported by
ECMO.
DrMorell. The second question is, I was a little surprised at the
poor outcome of postoperative ECMO, the patients who required
ECMO after transplant. Do you have some insight into why such
poor results with postoperative ECMO?
Dr Puri. Dr Morell, I take it that you are referring to a compar-
ison between pediatric and adult literature?
Dr Morell. I mean, we don’t have an extensive experience with
postoperative ECMO either, but I would expect a higher survival
among patients who only require postoperative ECMO if they
were reasonable candidates before operation and received reason-
able lungs. I just wonder, why do you think the survival was so
poor for patients who required postoperative ECMO?rdiovascular Surgery c Volume 140, Number 2 431
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XDr Puri. Just to put things into perspective, when the adult pop-
ulation requires postoperative ECMO, survivals range between
40% and 65%, depending on the study. For our patients, the general
perception was that if they required posttransplant ECMO, they
were sicker patients going into the procedure. I believe that we
have erroneously had a strategy of performing aggressive ventila-
tory strategies on freshly implanted lungs for longer periods, which
is something that we have reversed recently. Finally, in this partic-
ular patient population, there are somewhat higher incidences of
pulmonary hypertension and bronchiolitis obliterans than in the
general transplant population, either pediatric or adult.
DrMorell. I guess my final question is somewhat similar to that.
About 6% of your patients required postoperative ECMO, and I’m
just wondering whether you had a chance to look at any preopera-
tive variables that might help to identify patients who might be at
risk for postoperative ECMO.
Dr Puri. The combined incidence of bronchiolitis obliterans and
pulmonary hypertension was somewhat higher in the ECMO
group. It was 28% or so for the general population and 41% for
this particular group.
Dr Morell. Thank you.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). Dr Puri, am I
to understand that you had 3 patients in the preoperative ECMO
group with an indication of primary graft failure?
Dr Puri.One patient had primary graft failure and 2 patients had
bronchiolitis obliterans. I grouped them together as having PGD.
Dr Keshavjee. So the patient with the primary graft failure
would have been counted twice?
Dr Puri. Counted both in the preoperative and postoperative
ECMO groups.
Dr Keshavjee. But in the postoperative ECMO group the first
time around, and then the preoperative ECMO group, and then
again in the postoperative ECMO group?
Dr Puri. Correct.432 The Journal of Thoracic and Cardiovascular SurgDr Waleed Saleh (Riyadh, Saudi Arabia). You mentioned that
if you started the ECMO early, the outcome was better than with
a late start, and this is well documented in adult transplantation.
Do you have criteria to start the ECMO?
Dr Puri. A number of parameters are looked at by the team
taking care of patients: oxygenation, our ability to ventilate these
lungs without excessive airway pressures, systemic hemody-
namic compromise, and the trajectory of the clinical course in
the few hours after transplantation. In our earlier experience,
we did not have this insight, so we had long periods of using ag-
gressive ventilatory strategies on these freshly implanted lungs. I
think that was a bad idea, and we have recognized this lately and
are moving further and further toward earlier institution of
ECMO if we think the clinical trajectory is headed in the wrong
direction.
Dr Saleh. Thank you. Nice article.
Dr Puri. Dr Keshavjee, may I solicit a comment from you?
Dr Keshavjee. Sure.
Dr Puri. I believe that you have the most extensive North Amer-
ican NovaLung program. Are there any pediatric NovaLung appli-
cations that you’ve had, Dr Keshavjee?
Dr Keshavjee. Yes. Well, the NovaLung can run from 0.5 L to
4.5 L/min, so it’s capable of bridging kids to transplant. We have
only used the NovaLung as opposed to the standard ECMO setup
once, and we did it with the PA-to-LA setting. But I do think the
technology is getting better. The one thing that has come up, we
have all learned that in the posttransplant phase, if you’re going
to do it, just do it sooner. Every time we have regretted waiting lon-
ger, and we have had much smoother and shorter runs when we
have put it on early, almost to the point where you wonder whether
you could have gotten by without it. I think the most important
take-home message is that in the posttransplant period, you should
resort to it sooner than later, before you’ve got a very bad problem
on your hands.ery c August 2010
